株探米国株
日本語 英語
エドガーで原本を確認する
0000055785FALSE00000557852025-07-252025-07-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: July 25, 2025
(Date of earliest event reported)
K-C Logo Blue (JPG).jpg

KIMBERLY-CLARK CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 1-225 39-0394230
(State or other jurisdiction of incorporation) (Commission file number) (I.R.S. Employer Identification No.)
P.O. Box 619100
Dallas, TX
75261-9100
(Address of principal executive offices)
(Zip code)

Registrant’s telephone number, including area code: (972) 281-1200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock-$1.25 par value KMB The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 7.01    Regulation FD Disclosure.
As previously disclosed, on June 5, 2025, Kimberly-Clark Corporation ("Kimberly-Clark" or the "Company") announced the entry into an agreement with Suzano S.A. ("Suzano") to form a joint venture to be comprised of substantially all the operations of the Company's former International Family Care and Professional ("IFP") segment (the "IFP Business"). At the time of closing, Suzano along with certain of its wholly-owned subsidiaries will acquire a 51% interest in the joint venture for a purchase price of approximately $1.7 billion, subject to certain closing adjustments, and the Company will retain a 49% equity interest (the "IFP Transaction").
The Company determined the IFP Transaction represents a strategic shift that will have a major effect on its operations and financial results. As a result, effective in the second quarter of fiscal 2025, the results of the IFP Business are reported as discontinued operations in the Company's condensed consolidated financial statements.
To assist investors in comparing the Company's historical results, the Company is providing supplemental historical financial results reflecting the IFP Business as discontinued operations in Exhibit 99.1 hereto.

Item 9.01    Financial Statements and Exhibits.
(d)Exhibits.

99.1    Supplemental Historical Financial Information, dated July 25, 2025
101    Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
104    The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



KIMBERLY-CLARK CORPORATION
By:   /s/ Andrew Scribner
  Andrew Scribner
  Vice President and Controller
 

Date:    July 25, 2025


EX-99.1 2 exhibit991.htm EXHIBIT 99.1 Document

Exhibit 99.1


SUPPLEMENTAL HISTORICAL FINANCIAL INFORMATION

Unless the context otherwise requires, the terms "Corporation," "Kimberly-Clark," "K-C," "we," "our" and "us" refer to Kimberly-Clark Corporation and its consolidated subsidiaries.
Forward Looking Statements
Certain matters contained in this supplemental information concerning the business outlook, including raw material, energy and other input costs, our plans and expectations regarding the pending IFP Transaction, the anticipated charges and savings from the 2024 Transformation Initiative, cash flow and uses of cash, growth initiatives, innovations, marketing and other spending, net sales, anticipated currency rates and exchange risks, including the impact in Argentina and Türkiye, effective tax rate, contingencies and anticipated transactions of Kimberly-Clark, including dividends, share repurchases and pension contributions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and are based upon management's expectations and beliefs concerning future events impacting Kimberly-Clark. There can be no assurance that these future events will occur as anticipated or that our results will be as estimated. Forward-looking statements speak only as of the date they were made, and we undertake no obligation to publicly update them.
The assumptions used as a basis for the forward-looking statements include many estimates that, among other things, depend on the achievement of future cost savings and projected volume increases. In addition, many factors outside our control, including risks and uncertainties around the pending IFP Transaction (including risks related to delays or failure to complete the proposed transaction, the incurrence of significant transaction and separation costs, adverse market reactions, regulatory or legal challenges, and operational disruptions), risks that we are not able to realize the anticipated benefits of the 2024 Transformation Initiative (including risks related to disruptions to our business or operations or related to any delays in implementation), war in Ukraine (including the related responses of consumers, customers, and suppliers and sanctions issued by the U.S., the European Union, Russia or other countries), government trade or similar regulatory actions (including current and potential trade and tariff actions affecting the countries where we operate and the resulting negative impacts on our supply chain, commodity costs, and consumer spending), pandemics, epidemics, fluctuations in foreign currency exchange rates, the prices and availability of our raw materials, supply chain disruptions, disruptions in the capital and credit markets, counterparty defaults (including customers, suppliers and financial institutions with which we do business), failure to realize the expected benefits or synergies from our acquisition and disposition activity, impairment of goodwill and intangible assets and our projections of operating results and other factors that may affect our impairment testing, changes in customer preferences, severe weather conditions, regional instabilities and hostilities (including the war in Israel), potential competitive pressures on selling prices for our products, energy costs, general economic and political conditions globally and in the markets in which we do business, as well as our ability to maintain key customer relationships, could affect the realization of these estimates.
The factors described under Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 (the "2024 Form 10-K"), or in our other SEC filings, among others, could cause our future results to differ from those expressed in any forward-looking statements made by us or on our behalf. Other factors not presently known to us or that we presently consider immaterial could also affect our business operations and financial results.
Background
On June 5, 2025, we announced that the Company will form a joint venture with Suzano S.A. ("Suzano") and Suzano International Holding B.V., a wholly-owned subsidiary of Suzano ("Buyer"), comprised of substantially all the operations of the Company's former International Family Care and Professional segment (the "IFP Business"). To facilitate this transaction, we entered into an Equity and Asset Purchase Agreement (the "Purchase Agreement") with Buyer, pursuant to which we will, among other things, effectuate a reorganization through the transfer of certain assets, liabilities and equity interests of the IFP Business to Kimberly-Clark IFP NewCo B.V., an indirect wholly-owned subsidiary of the Company (the "Joint Venture"). At the time of closing, which is expected to take place in mid-2026 and will only take place following the satisfaction of consultation requirements and customary closing conditions, including obtaining required regulatory approvals, Buyer will acquire a 51% interest in the Joint Venture for a purchase price of approximately $1.7 billion, subject to certain closing adjustments set forth in the Purchase Agreement, and we will retain a 49% equity interest (the "IFP Transaction").



In accordance with ASC 205, Presentation of Financial Statements, we determined the IFP Transaction represents a strategic shift that will have a major effect on our operations and financial results. Accordingly, effective in the second quarter of fiscal 2025, the results of the IFP Business are reported as discontinued operations and excluded from both continuing operations and segment results for all reporting periods (including comparable historical periods).
Segment Reporting
As discussed above, the results of the IFP Business are excluded from segment results for all reporting periods (including comparable historical periods). This includes certain costs that were previously allocated to the International Personal Care ("IPC") segment that relate to assets or activities that are part of the IFP Transaction. These costs have been removed from the results of the IPC segment and are reported as discontinued operations.
Additionally, certain operations and commercial activities of the former IFP segment retained by the Company are now reported in the North America ("NA") and IPC segments.
As a result, the Company's continuing operations are now organized into two reportable segments defined by geographic region: North America and International Personal Care.
Further, Corporate and Other now includes the following:
•Operations of the former IFP segment that were divested prior to the IFP Transaction and therefore not reported as discontinued operations.
•Costs previously allocated to the former IFP segment that are not directly attributable to the operations nor included in the IFP Transaction and therefore are not reported as discontinued operations.
For informational purposes only, we have recast our historical financial and segment results to reflect the presentation of the IFP Business as discontinued operations for each of the quarters ended March 31, 2025, December 31, 2024, September 30, 2024, June 30, 2024, and March 31, 2024, and the years ended December 31, 2024 and December 31, 2023. These changes had no impact on our consolidated financial results for any of the periods presented in our Quarterly Reports on Form 10-Q for the respective interim periods outlined above, or any of the annual periods presented in our 2024 Form 10-K.
The following unaudited financial information is based on our historical consolidated financial statements after giving effect to the reporting of the IFP Business as discontinued operations. This supplemental information should be read together with our unaudited condensed consolidated financial statements and related notes in each of our Quarterly Reports on Form 10-Q for the respective interim periods outlined above, and our audited consolidated financial statements and related notes in our 2024 Form 10-K. The financial information contained in this supplemental information is not indicative of future or annual results.




Kimberly-Clark Corporation and Subsidiaries
Condensed Consolidated Statements of Income
Recast to Present the IFP Business as Discontinued Operations
(Unaudited)


Year Ended December 31
(In millions, except per share amounts) 2024 2023
Net Sales $ 16,805  $ 17,146 
Cost of products sold 10,516  10,877 
Gross Profit 6,289  6,269 
Marketing, research and general expenses 3,930  3,615 
Impairment of intangible assets 97  658 
Other (income) and expense, net (438) 68 
Operating Profit 2,700  1,928 
Nonoperating expense (60) (95)
Interest income 48  66 
Interest expense (270) (293)
Income from Continuing Operations Before Income Taxes and Equity Interests 2,418  1,606 
Provision for income taxes (442) (343)
Income from Continuing Operations Before Equity Interests 1,976  1,263 
Share of net income of equity companies 216  196 
Income from Continuing Operations 2,192  1,459 
Income from Discontinued Operations, Net of Income Taxes 386  305 
Net Income 2,578  1,764 
Net income attributable to noncontrolling interests (33) — 
Net Income Attributable to Kimberly-Clark Corporation $ 2,545  $ 1,764 
Per Share Basis
Net Income Attributable to Kimberly-Clark Corporation
Basic:
Continuing operations $ 6.43  $ 4.32 
Discontinued operations 1.15  0.90 
Basic Earnings per Share $ 7.58  $ 5.22 
Diluted:
Continuing operations $ 6.41  $ 4.31 
Discontinued operations 1.14  0.90 
Diluted Earnings per Share $ 7.55  $ 5.21 














Kimberly-Clark Corporation and Subsidiaries
Condensed Consolidated Statements of Income
Recast to Present the IFP Business as Discontinued Operations
(Unaudited)

Three Months Ended
March 31 December 31 September 30 June 30 March 31
(In millions, except per share amounts) 2025 2024 2024 2024 2024
Net Sales $ 4,054  $ 4,104  $ 4,144  $ 4,231  $ 4,326 
Cost of products sold 2,545  2,659  2,580  2,637  2,640 
Gross Profit 1,509  1,445  1,564  1,594  1,686 
Marketing, research and general expenses 855  1,006  1,006  967  951 
Impairment of intangible assets —  —  97  —  — 
Other (income) and expense, net 23  19  (565) 88  20 
Operating Profit 631  420  1,026  539  715 
Nonoperating expense (17) (15) (15) (15) (15)
Interest income 11  18  10 
Interest expense (64) (64) (67) (72) (67)
Income from Continuing Operations Before Income Taxes and Equity Interests 557  352  962  461  643 
Provision for income taxes (131) (47) (187) (60) (148)
Income from Continuing Operations Before Equity Interests 426  305  775  401  495 
Share of net income of equity companies 44  44  48  63  61 
Income from Continuing Operations 470  349  823  464  556 
Income from Discontinued Operations, Net of Income Taxes 103  103  92  89  102 
Net Income 573  452  915  553  658 
Net income attributable to noncontrolling interests (6) (5) (8) (9) (11)
Net Income Attributable to Kimberly-Clark Corporation $ 567  $ 447  $ 907  $ 544  $ 647 
Per Share Basis
Net Income Attributable to Kimberly-Clark Corporation
Basic:
Continuing operations $ 1.40  $ 1.03  $ 2.43  $ 1.35  $ 1.62 
Discontinued operations 0.31  0.31  0.27  0.26  0.30 
Basic Earnings per Share $ 1.71  $ 1.34  $ 2.70  $ 1.61  $ 1.92 
Diluted:
Continuing operations $ 1.39  $ 1.03  $ 2.42  $ 1.35  $ 1.61 
Discontinued operations 0.31  0.31  0.27  0.26  0.30 
Diluted Earnings per Share $ 1.70  $ 1.34  $ 2.69  $ 1.61  $ 1.91 







Kimberly-Clark Corporation and Subsidiaries
Discontinued Operations of the IFP Business
(Unaudited)


Year Ended December 31
(In millions) 2024 2023
Net Sales $ 3,253  $ 3,285 
Cost of products sold 2,362  2,522 
Gross Profit 891  763 
Marketing, research and general expenses 381  346 
Other (income) and expense, net — 
Operating Profit 510  416 
Nonoperating expense (1) (1)
Income from Discontinued Operations Before Income Taxes 509  415 
Provision for income taxes (123) (110)
Income from Discontinued Operations, Net of Income Taxes $ 386  $ 305 


Three Months Ended
March 31 December 31 September 30 June 30 March 31
(In millions) 2025 2024 2024 2024 2024
Net Sales $ 786  $ 824  $ 808  $ 798  $ 823 
Cost of products sold 562  594  588  582  598 
Gross Profit 224  230  220  216  225 
Marketing, research and general expenses 86  103  91  99  88 
Other (income) and expense, net —  (1) (1)
Operating Profit 138  128  128  116  138 
Nonoperating expense (1) (1) —  —  — 
Income from Discontinued Operations Before Income Taxes 137  127  128  116  138 
Provision for income taxes (34) (24) (36) (27) (36)
Income from Discontinued Operations, Net of Income Taxes $ 103  $ 103  $ 92  $ 89  $ 102 

















Kimberly-Clark Corporation and Subsidiaries
Segment Reporting
Recast to Reflect the IFP Business as Discontinued Operations
(Unaudited)
Year Ended December 31
(In millions) 2024 2023
Net Sales
NA $ 11,017  $ 10,996 
IPC 5,743  5,940 
Segment Net Sales(a)
16,760  16,936 
Corporate & Other(b)
45  210 
Total Net Sales $ 16,805  $ 17,146 
Operating Profit
NA $ 2,542  $ 2,514 
IPC 826  673 
Segment Operating Profit(a)
3,368  3,187 
Corporate & Other(b)
(668) (1,259)
Total Operating Profit $ 2,700  $ 1,928 
Three Months Ended
March 31 December 31 September 30 June 30 March 31
(In millions) 2025 2024 2024 2024 2024
Net Sales
NA $ 2,668  $ 2,723  $ 2,735  $ 2,783  $ 2,776 
IPC 1,386  1,381  1,409  1,427  1,526 
Segment Net Sales(a)
4,054  4,104  4,144  4,210  4,302 
Corporate & Other(b)
—  —  —  21  24 
Total Net Sales $ 4,054  $ 4,104  $ 4,144  $ 4,231  $ 4,326 
Operating Profit
NA $ 678  $ 550  $ 641  $ 682  $ 669 
IPC 201  165  201  209  251 
Segment Operating Profit(a)
879  715  842  891  920 
Corporate & Other(b)
(248) (295) 184  (352) (205)
Total Operating Profit $ 631  $ 420  $ 1,026  $ 539  $ 715 
(a)    Segment Net Sales and Segment Operating Profit are non-GAAP financial measures as they exclude certain results included within Corporate & Other, as discussed below. Refer to "Summary of Non-GAAP Financial Measures" below for further discussion of how we utilize non-GAAP financial measures. As shown above, we have included a reconciliation to Total Net Sales and Total Operating Profit, as determined in accordance with GAAP.
(b)    Corporate & Other includes income and expense not associated with the ongoing operations of the segments, including certain operations of the former IFP segment that were divested prior to the IFP Transaction and costs previously allocated to the former IFP segment that aren't eligible to be reported as discontinued operations.





SUMMARY OF NON-GAAP FINANCIAL MEASURES
The following provides the reconciliation of the non-GAAP financial measures summarized below to the most closely related GAAP measure. These measures include: Organic Sales Growth, Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Earnings per Share, and Adjusted Effective Tax Rate. These measures are provided on a continuing operations basis and exclude the impact of discontinued operations.
•Organic Sales Growth is defined as the change in Net Sales, as determined in accordance with U.S. GAAP, excluding the impacts of currency translation and divestitures and business exits.
•Adjusted Gross and Operating Profit, Adjusted Earnings per Share, and Adjusted Effective Tax Rate are defined as Gross Profit, Operating Profit, Diluted Earnings per Share, and Effective Tax Rate, respectively, as determined in accordance with U.S. GAAP, excluding the impacts of certain items that management believes do not reflect our underlying operations.
The income tax effect of these non-GAAP items on the Company's Adjusted Earnings per Share is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. The impact of these non-GAAP items on the Company’s effective tax rate represents the difference in the effective tax rate calculated with and without the non-GAAP adjustment on Income from Continuing Operations Before Income Taxes and Equity Interests and Provision for income taxes.
We use these non-GAAP financial measures to assist in comparing our performance on a consistent basis for purposes of business decision making by removing the impact of certain items that we do not believe reflect our underlying and ongoing operations. We believe that presenting these non-GAAP financial measures is useful to investors because it (i) provides investors with meaningful supplemental information regarding financial performance by excluding certain items, (ii) permits investors to view performance using the same tools that management uses to budget, make operating and strategic decisions, and evaluate historical performance, and (iii) otherwise provides supplemental information that may be useful to investors in evaluating our results. We believe that the presentation of these non-GAAP financial measures, when considered together with the corresponding U.S. GAAP financial measures and the reconciliation to those measures, provides investors with additional understanding of the factors and trends affecting our business than could be obtained absent these disclosures.
These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for the comparable GAAP measures, and they should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. There are limitations to these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled measures of other companies due to potential differences in methods of calculation and items being excluded. We compensate for these limitations by using these non-GAAP financial measures as a supplement to the GAAP measures and by providing reconciliations of the non-GAAP and comparable GAAP financial measures. For further information about the non-GAAP adjustments included below, refer to our Annual Report on Form 10-K for the year ended December 31, 2024.
Summary of Non-GAAP financial measures:
Year Ended December 31
2024 2023
Adjusted Gross Profit $ 6,433 $ 6,284
Adjusted Operating Profit 2,727 2,542
Adjusted Earnings per Share 6.16 5.67
Adjusted Effective Tax Rate 22.7  % 22.6  %
Three Months Ended
March 31 December 31 September 30 June 30 March 31
2025 2024 2024 2024 2024
Adjusted Gross Profit $ 1,562 $ 1,513 $ 1,595 $ 1,639 $ 1,686
Adjusted Operating Profit 706 556 682 729 760
Adjusted Earnings per Share 1.62 1.19 1.56 1.70 1.71
Adjusted Effective Tax Rate 20.7  % 26.8  % 21.5  % 20.4  % 23.1  %



The following tables provide a reconciliation of Organic Sales Growth from continuing operations:
Year Ended December 31
Percent change vs. the prior year period 2024 2023
Net Sales Growth (2.0) 1.1 
Currency Translation 4.2  3.0 
Divestitures and Business Exits 1.6  0.7 
Organic Sales Growth(a)
3.9  4.8 
Three Months Ended
Percent change vs. the prior year period March 31 December 31 September 30 June 30 March 31
2025 2024 2024 2024 2024
Net Sales Growth (6.3) (1.4) (4.1) (2.1) (0.2)
Currency Translation 2.4  2.2  3.8  4.9  6.0 
Divestitures and Business Exits 2.5  1.7  1.8  1.2  1.4 
Organic Sales Growth(a)
(1.4) 2.5  1.5  4.0  7.3 
(a)    Tables may not foot due to rounding.
The following tables provide a reconciliation of Adjusted Gross Profit from continuing operations:
Year Ended December 31
2024 2023
Gross Profit $ 6,289  $ 6,269 
2024 Transformation Initiative 144  — 
Sale of Brazil Tissue and Professional Business —  15 
Adjusted Gross Profit $ 6,433  $ 6,284 
Three Months Ended
March 31 December 31 September 30 June 30 March 31
2025 2024 2024 2024 2024
Gross Profit $ 1,509  $ 1,445  $ 1,564  $ 1,594  $ 1,686 
2024 Transformation Initiative 53  68  31  45  — 
Adjusted Gross Profit $ 1,562  $ 1,513  $ 1,595  $ 1,639  $ 1,686 
The following tables provide a reconciliation of Adjusted Operating Profit from continuing operations:
Year Ended December 31
2024 2023
Operating Profit $ 2,700  $ 1,928 
2024 Transformation Initiative 456  — 
Sale of Personal Protective Equipment Business (565) — 
Impairment of Intangible Assets 97  658 
Legal Expense 39  — 
Sale of Brazil Tissue and Professional Business —  (44)
Adjusted Operating Profit $ 2,727  $ 2,542 



Three Months Ended
March 31 December 31 September 30 June 30 March 31
2025 2024 2024 2024 2024
Operating Profit $ 631  $ 420  $ 1,026  $ 539  $ 715 
2024 Transformation Initiative 75  97  124  190  45 
Sale of Personal Protective Equipment Business —  —  (565) —  — 
Impairment of Intangible Assets —  —  97  —  — 
Legal Expense —  39  —  —  — 
Adjusted Operating Profit $ 706  $ 556  $ 682  $ 729  $ 760 
The following tables provide a reconciliation of Adjusted Earnings per Share from continuing operations:
Year Ended December 31
2024 2023
Diluted Earnings per Share $ 6.41  $ 4.31 
2024 Transformation Initiative 1.01  — 
Sale of Personal Protective Equipment Business (1.34) — 
Impairment of Intangible Assets 0.17  1.36 
Legal Expense 0.11  — 
Softex Tax Reserve Release (0.20) — 
Sale of Brazil Tissue and Professional Business —  (0.08)
Pension Settlements —  0.08 
Adjusted Earnings per Share(a)
$ 6.16  $ 5.67 
Three Months Ended
March 31 December 31 September 30 June 30 March 31
2025 2024 2024 2024 2024
Diluted Earnings per Share $ 1.39  $ 1.03  $ 2.42  $ 1.35  $ 1.61 
2024 Transformation Initiative 0.23  0.25  0.31  0.35  0.10 
Sale of Personal Protective Equipment Business —  —  (1.34) —  — 
Impairment of Intangible Assets —  —  0.17  —  — 
Legal Expense —  0.11  —  —  — 
Softex Tax Reserve Release —  (0.20) —  —  — 
Adjusted Earnings per Share(a)
$ 1.62  $ 1.19  $ 1.56  $ 1.70  $ 1.71 
(a)    The non-GAAP adjustments included above are presented net of tax. The income tax effect of these non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. Refer to the Adjusted Effective Tax Rate reconciliation below for the tax effect of these adjustments on the Company's reported Provision for income taxes.



The following tables provide a reconciliation of the continuing operations Adjusted Effective Tax Rate:
Year Ended December 31
2024 2023
Income from Continuing Operations Before Income Taxes and Equity Interests Provision for Income Taxes Income from Continuing Operations Before Income Taxes and Equity Interests Provision for Income Taxes
As Reported $ 2,418  $ (442) $ 1,606  $ (343)
2024 Transformation Initiative 457  (118) —  — 
Sale of Personal Protective Equipment Business (565) 112  —  — 
Impairment of Intangible Assets 97  (40) 658  (175)
Legal Expense 39  (1) —  — 
Softex Tax Reserve Release —  (67) —  — 
Sale of Brazil Tissue and Professional Business —  —  (44) 18 
Pension Settlements —  —  35  (9)
As Adjusted $ 2,446  $ (556) $ 2,255  $ (509)
Effective Tax Rate:
As Reported 18.3  % 21.4  %
As Adjusted 22.7  % 22.6  %

Three Months Ended March 31
2025
Income from Continuing Operations Before Income Taxes and Equity Interests Provision for Income Taxes
As Reported $ 557  $ (131)
2024 Transformation Initiative 77  — 
As Adjusted $ 634  $ (131)
Effective Tax Rate:
As Reported 23.5  %
As Adjusted 20.7  %



Three Months Ended
December 31 September 30 June 30 March 31
2024 2024 2024 2024
Income from Continuing Operations Before Income Taxes and Equity Interests Provision for Income Taxes Income from Continuing Operations Before Income Taxes and Equity Interests Provision for Income Taxes Income from Continuing Operations Before Income Taxes and Equity Interests Provision for Income Taxes Income from Continuing Operations Before Income Taxes and Equity Interests Provision for Income Taxes
As Reported $ 352  $ (47) $ 962  $ (187) $ 461  $ (60) $ 643  $ (148)
2024 Transformation Initiative 98  (16) 124  (18) 190  (73) 45  (11)
Sale of Personal Protective Equipment Business —  —  (565) 112  —  —  —  — 
Impairment of Intangible Assets —  —  97  (40) —  —  —  — 
Legal Expense 39  (1) —  —  —  —  —  — 
Softex Tax Reserve Release —  (67) —  —  —  —  —  — 
As Adjusted $ 489  $ (131) $ 618  $ (133) $ 651  $ (133) $ 688  $ (159)
Effective Tax Rate:
As Reported 13.4  % 19.4  % 13.0  % 23.0  %
As Adjusted 26.8  % 21.5  % 20.4  % 23.1  %